Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has appointed Yrjö Wichmann as its interim CFO, effective April 15, 2024. He succeeds James O’Brien, who is leaving Faron to pursue another career…
Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has appointed Yrjö Wichmann as its interim CFO, effective April 15, 2024. He succeeds James O’Brien, who is leaving Faron to pursue another career…
…
…